Want to see AU:AGN full AI Analyst Report?
AGN Stock Chart & Stats
AU$0.20
<AU$0.01(3.23%)
At close: 4:00 PM EDT
AU$0.20
<AU$0.01(3.23%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.35
Previous CloseN/A
Volume188.94K
Average Volume (3M)72.87K
Market Cap
AU$19.27M
Enterprise ValueAU$32.86
Total Cash (Recent Filing)AU$6.36M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding128,456,710
10 Day Avg. Volume71,743
30 Day Avg. Volume72,869
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$28.10M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt limits leverage and interest-burden risk, giving Argenica greater flexibility to allocate capital toward research and development. Although equity has declined, the absence of borrowings provides a more resilient funding structure than a similarly loss-making company carrying material debt.
Prior Revenue ExpansionRevenue growth from 2022 through 2025 shows that Argenica previously expanded its commercial or development-related income base. This demonstrates some ability to generate revenue, even though the subsequent fall to zero in 2026 means the earlier growth has not yet been established as durable.
Improved 2026 LossThe improvement in 2026 compared with the notably weaker 2025 result suggests some progress in controlling or reducing losses. If sustained, this could slow equity erosion and extend financial runway, but the company has not yet converted that improvement into sustainable profitability.
Bears Say
Zero 2026 RevenueThe collapse to zero revenue indicates that recent income generation is not dependable and that commercial momentum has weakened sharply. Without recurring revenue, Argenica remains more dependent on external funding or future development milestones to support operations and advance its pipeline.
Persistent Operating LossesRecurring operating and net losses show that the current business model has not reached economic self-sufficiency. Continued losses can erode equity, constrain investment in drug development, and make future financial performance heavily dependent on successful clinical or commercial progress.
Ongoing Cash BurnPersistent negative operating cash flow means Argenica is consuming cash rather than funding its activities internally. This creates an ongoing need for financing or other capital sources, potentially limiting strategic flexibility and increasing the importance of preserving available funds.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.09 and its highest was AU$0.34 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$19.27M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 154 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AGN Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$20.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―